Advanced search
Start date

Encapsulation of curcumin in BioMOF-100 functionalized with folate: development and evaluation of potential in the treatment of Breast Cancer

Grant number: 17/26065-2
Support type:Scholarships in Brazil - Doctorate
Effective date (Start): July 01, 2018
Effective date (End): July 31, 2021
Field of knowledge:Health Sciences - Pharmacy - Pharmaceutical Technology
Principal Investigator:Marlus Chorilli
Grantee:Renata Carolina Alves
Home Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
Associated scholarship(s):18/26405-0 - Surface modification with folic acid in a curcumin- loaded mesoporous metal-organic framework by "click" reactions, BE.EP.DR


Breast Cancer is the most frequent and the most frequent cause of Cancer death in women, representing the fifth leading cause of Cancer death in general. Particular interest are unfavorable triple negative breast tumors which may express folate receptors, which may be useful for designing strategies for targeting the tumor therapy. Curcumin (CCM), extracted from the curcuma longa plant, has chemopreventive and antitumor activities against some aggressive and recurrent Cancer s, such as breast Cancer. Despite its great potential in antitumor therapy, CCM has limitations, which include low solubility in water at physiological pH and acid conditions, rapid hydrolysis at alkaline pH and instability in the presence of light. In this way, a release system that allows efficient administration of CCM is of paramount importance. In this sense, Biocompatible Metal Organic Frameworks (BioMOFs), polymers of coordination, can be promising and attractive for incorporation and modified release of this drug. Thus, this project aims to encapsulate CCM in folate-functionalized BioMOF-100 and to evaluate the potential of this carrier in the treatment of Breast Cancer in vitro and in vivo models. The physicochemical characterization of the system will involve evaluations of crystallinity, morphology, thermal stability, drug encapsulation efficiency and quantification of folate present in the carrier after functionalization. Finally, the system will be evaluated in vitro by cytotoxicity assay in cell lines that express or not the folate receptor and in vivo, in an acute toxicity model and triple negative breast Cancer. (AU)